ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
17.52
+0.08 (0.46%)
At close: May 12, 2025, 4:00 PM
17.50
-0.02 (-0.11%)
After-hours: May 12, 2025, 5:05 PM EDT
ACADIA Pharmaceuticals Revenue
ACADIA Pharmaceuticals had revenue of $244.32M in the quarter ending March 31, 2025, with 18.70% growth. This brings the company's revenue in the last twelve months to $996.28M, up 22.42% year-over-year. In the year 2024, ACADIA Pharmaceuticals had annual revenue of $957.80M with 31.85% growth.
Revenue (ttm)
$996.28M
Revenue Growth
+22.42%
P/S Ratio
2.91
Revenue / Employee
$1,523,369
Employees
654
Market Cap
2.93B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 957.80M | 231.36M | 31.85% |
Dec 31, 2023 | 726.44M | 209.20M | 40.45% |
Dec 31, 2022 | 517.24M | 33.09M | 6.83% |
Dec 31, 2021 | 484.15M | 42.39M | 9.60% |
Dec 31, 2020 | 441.76M | 102.68M | 30.28% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ACAD News
- 4 days ago - ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 5 days ago - Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview - Business Wire
- 7 days ago - Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference - Business Wire
- 19 days ago - Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025 - Business Wire
- 4 weeks ago - Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - Business Wire
- 2 months ago - Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med - Business Wire
- 2 months ago - Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study - Business Wire